# NCT01776840 (NCT01776840)

> A Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Given in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma

No report yet. It can be ordered.

- Drugs tested: ibrutinib
- Indication: newly diagnosed mantle cell lymphoma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT01776840
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Janssen Research & Development, LLC
- Conditions: Mantle Cell Lymphoma
- Interventions: Bendamustine; Rituximab; Ibrutinib; Placebo
- Enrollment: 523
- Primary outcome: Progression-free Survival (PFS)

## Indexed commentary on NCT01776840 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 3 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=nct01776840